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Abstract
Introduction: Recent models capturing the pathophysiology of sepsis and ex-vivo data from patients are
speculating about immunosuppression in the so-called late phase of sepsis. Clinical data regarding survival and
microbiological burden are missing. The aim of this study was to determine the clinical significance of the ‘late
phase’ of sepsis with respect to overall survival and occurrence of microbiological findings.
Methods: In a retrospective trial, 16,041 patient charts from a university intensive care unit were screened, and 999
patients with severe sepsis or septic shock were identified. Three phases were established according to the
mortality peaks which were separated by two distinct nadirs: phase I (days 1 to 5), phase II (days 6 to 15) and
phase III (days 16 to 150). Patients were analyzed for outcome, SOFA scores, procalcitonin levels, antimicrobial
treatment, dialysis, mechanical ventilation and results of blood cultures during their hospital stay.
Results: Out of 999 enrolled patients, 308 died during the course of sepsis presenting a characteristic mortality rate
(30.8%) with three distinct mortality peaks (at days 2, 7 and 17). Overall 36.7% of all deaths occurred in the early
phase (phase I) and 63.3% during the later phases (phase II + III). In total 2,117 blood cultures were drawn. In
phase I, 882 blood cultures were drawn, representing a sampling rate of 88% with a positive rate of 14.9%. In
phase II, 461 samples were taken, indicating a sampling rate of 52% and a positive rate of 11.3%. Within phase III,
524 samples were obtained representing a sampling rate of 66% with a positive rate of 15.3%, which was
significantly higher compared to the positive rate of phase II and similar to phase I. In particular, the rate of
typically opportunistic bacteria increased significantly from 9% in phase I up to 18% in phase III. The same is true
for Candida spp. (phase I 13%, phase III 30%).
Conclusions: The later phase of sepsis is associated with a significant re-increase of positive blood culture results,
especially regarding opportunistic bacteria and fungi. These observations warrant further studies focusing on the
underlying mechanisms resulting in this outcome burden in the later phase of sepsis.
Introduction
Despite aggressive supportive care to improve treatment
options and outcome, sepsis and its sequelae remain a
leading cause of death in intensive care units [1]. Exten-
sive studies investigating the host responses during sep-
sis have revealed that the late phase of sepsis is
dominated by a status of immune suppression with
respect to missing or widespread depressed innate, as
well as adaptive, immune defense mechanisms. Since
various authors introduced the intriguing model of a
phase-dependent variation of immune activity [2-4], the
concept of an anergic immune system is held responsi-
ble as a principal mechanism and cause of death in
patients with sepsis [5,6]. However, the concept itself,
but more the impact of sequential hyper- and hypo-
inflammatory phases, has been discussed controversially
[7-9]. The lack of tools assessing the individual immune
status of patients at the bedside and the complex patho-
physiological processes, which are often overlapping,
have so far limited the meaning of such concepts
describing hyper- and hypo-inflammatory immune
phases for the clinician. Confirmatory studies demon-
strating the clinical significance, especially of the so-
called late phase in sepsis, are largely missing. We,
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phase during the course of sepsis would be accompanied
by higher death rates and higher rates of positive blood
culture results, especially by typically opportunistic bac-
teria. The latter might be interpreted as a hint for an
underlying immune suppressive status, which has been
suggested by many studies investigating separate
immune defense mechanisms in patients suffering from
sepsis [2,3,6,9].
Materials and methods
To clarify this question we used a large database of
patient records from daily practice and performed a ret-
rospective trial enrolling patients admitted from 1 Janu-
ary 2006 to 31 December 2009 to the intensive care unit
of the Jena university hospital. The study was approved
by the institutional review board of Friedrich Schiller
University Hospital, Jena, Germany (3080-03/11).
Informed consent was waived due to the anonymous
nature of the analysis. A total of 16,041 patients were
screened according to the criteria of the American Col-
lege of Chest Physicians/Society of Critical Care Medi-
cine (ACCP/SCCM) for severe sepsis or septic shock
[10,11]. We identified 999 patients qualifying for severe
sepsis or septic shock and evaluated demographics, clini-
cal characteristics, disease severity measured by SOFA
score [12,13], procalcitonin levels (PCT), requirement of
renal replacement therapy and mechanical ventilation,
and outcome of patients, as well as the results of micro-
biological blood cultures and antimicrobial treatment.
By the observed trajectory of mortality, periods with
different mortality rates were identified and classified by
the nadirs, yielding in the definition of three distinct
phases: Phase I from Day 1 until Day 5, phase II from
Day 6 until Day 15 and phase III from Day 16 until the
end of the observation period at Day 150. To investigate
the relevance of the various phases, analyses of all
obtained blood cultures with respect to their date of
sampling during patients’ hospital stay were performed.
In addition, samples taken 10 days prior to clinical diag-
nosis of sepsis were included and this time period was
defined as phase 0 (Day -10 to Day -1). Coagulase nega-
tive staphylococci (CNS) were interpreted as skin con-
tamination of no importance and presented separately.
Furthermore, epidemiology of microorganisms in the
different phases was analyzed. Beside the total number
of positive findings, the relative numbers of drawn
blood cultures in relation to the number of patients
alive during that period and, in particular, the rate of
positive findings per obtained samples during the corre-
sponding phase were also analyzed. Additionally, the
practice of antimicrobial treatment and clinical charac-
teristics of patients were studied dependent of the
defined phases and dependent of the results from the
obtained blood cultures at the day of sampling.
Statistics
All data are reported as relative numbers, including ori-
ginal absolute numbers. A Chi-square test was used for
comparisons of categorical data. Continuous data across
multiple groups were compared by ANOVA testing with
Bonferroni adjustment. P-values < 0.05 were considered
significant. Data were analyzed using SPSS software
(version 13) from SPSS Inc. (Chicago, IL, USA).
Results
Demographics, clinical characteristics and outcome
An overview of the demographics and clinical character-
istics from the identified patients with severe sepsis or
septic shock is given in Table 1. Out of these 999
patients, 308 died during the course of severe sepsis or
septic shock. The outcome data plotted from first onset
of sepsis until Day 36 of these enrolled patients were
characterized by three peaks of increased mortality
rates. The first one occurred at Day 2 after reported
diagnosis, the second one at Day 7 and the last one at
around Day 17 (Figure 1). In agreement with the
addressed concept of a late phase of sepsis, the second
and third maximum values might pertain to this phase
of sepsis. The further analyses were strictly performed
according to the defined phases by the observed nadirs
of mortality rate (phase I: Day 1 until Day 5, phase II:
D a y6u n t i lD a y1 5 ,p h a s eI I I :D a y1 6u n t i lt h ee n do f
the observation period at Day 150).
Table 1 Demographics and clinical characteristics of
enrolled patients with severe sepsis or septic shock
Demographics and clinical characteristics
Gender, male/female, # 660/339
Age (years), median (IQR) 67 (56 to 75)
BMI (kg/m
2), median (IQR) 26.3 (23.9 to 29.6)
APACHE II Score at admission, median (IQR) 14 (11 to 19)
Type of ICU admission
Medical, # (%) 410 (41)
Surgical, # (%) 589 (59)
Co-morbid conditions, # (%)
Hypertension 533 (53)
Diabetes 305 (31)
Cancer 272 (27)
Intestinal ischemia 96 (10)
Liver failure 78 (8)
Characteristics of patients enrolled. BMI, body mass index; APACHE II, Acute
Physiology and Chronic Health Evaluation II score was calculated at ICU
admission; LOS, length of stay; IQR, interquartile range; #, numbers; %, relative
number.
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D a y5d u r i n gp h a s eIa n d6 3 . 3 %( 3 0 . 8 %p h a s eI Ia n d
32.5% phase III) during the following period (phase I vs.
phase II + III P ≤ 0.01; c
2 test) (Table 2). The mortality
rate of the later phase was 22% (10.7% phase II and
12.6% phase III) - significantly higher than in the early
phase I with 11.3% (phase I vs. phase II + III P ≤ 0.01;
c
2 test). With regard to these numbers, the later phases
of sepsis, phase II and, especially, phase III, demon-
strated a broad clinical significance.
Positive blood cultures without CNS
In total, 2,117 blood cultures were drawn. Prior to diag-
nosis in phase 0, 250 blood cultures were obtained,
equaling a sampling rate of 25%, of which 9.6% were
positive. During phase I, 882 blood cultures were drawn,
representing a sampling rate of 88.3% with a positive
rate of 14.9%. For the 886 patients alive in phase II, 461
samples were taken indicating a sampling rate of 52%
and a positive rate of 11.3%. In the last phase III from
Day 16 until Day 150, 524 samples were obtained repre-
senting a sampling rate of 66.2% with a positive rate of
15.3% (Table 2). There was a significant reduction in
the numbers of drawn specimens per patient in phase II
(phase II vs. phase I P ≤ 0.01; c
2 test) and a significant
re-increase in phase III (phase III vs. phase II P ≤ 0.01;
c
2 test). A significant increase in the rate of positive
blood cultures was found in phase I compared to phase
0( P ≤ 0.05; c
2 test), the rate of positive findings
dropped in phase II (P ≤ 0.05; c
2 test) and rose again in
phase III (P ≤ 0.05; c
2 test) comparable to levels of
phase I (P > 0.05; c
2 test).
Epidemiology of microorganisms
A detailed overview of the epidemiology of isolated
microorganisms depicted according to the different
Figure 1 Distribution of non survivors and positive blood cultures during sepsis. Relative numbers of deaths per day from 999 patients
with severe sepsis or septic shock according to ACCP/SCCM criteria are shown from the day of onset/diagnosis until observation Day 36. Three
phases were defined, characterized by the nadir at Day 5 and Day 15. Also, the average rates of positive blood cultures without CNS in a five-
day period with respect to sampling times are shown. bc, blood cultures; CNS, Coagulase negative staphylococci; #, numbers; %, relative number.
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short overview in Table 3 (see also, Additional file 1).
The rate of bacteria classified as typically opportunistic
bacteria (TOB) increased over time from 7.7% in phase
0 up to 17.8% in phase III. In phase III, TOB were sig-
nificantly more often identified in comparison to phase
1 (phase I vs. phase III P ≤ 0.05; c
2 test). Furthermore,
the rate of isolated Candida spp. increased from 7.7% in
phase 0 up to 35.7% in phase II and 30% in phase III.
Both later phases were characterized by a significantly
higher rate of Candida spp. compared to both earlier
phases (phase II or III vs. phase 0 or I; P ≤ 0.05; c
2
test). The rate of CNS ranged from 50.9% in phase 0 to
26.7% in phase I (phase I vs. phases 0, II, III; P ≤ 0.01;
c
2 test).
Severity and use of antimicrobials
In the severity of disease measured by SOFA score, as
well as in the course of PCT as a prototypic biomarker
of infection, significant differences were found between
the various phases. In phase I, both parameters peaked
with the highest levels (phase I vs. phases 0, II, III; P ≤
0.01; ANOVA, Table 4) and fell over time to reach the
lowest levels at phase III (phase III vs. phases 0, I, II; P
≤ 0.01; ANOVA). The same was true for the require-
ment of mechanical ventilation with the highest rate of
90.9% in phase I (phase I vs. phases 0, II, III; P ≤ 0.01;
c
2 test). In the use of renal replacement therapy with
exception of phase 0, in which only 13% and, therefore,
significantly fewer patients needed dialyses, no signifi-
cant differences between the phases were found (phase
0 vs. phases I, II, III; P ≤ 0.01; ANOVA).
The rates of antimycotic therapy increased signifi-
cantly over time with the highest rate of 28.7% during
phase III (phase III vs. phases 0, I, II; P ≤ 0.01; c
2 test).
Azole antifungal drugs were prescribed most often.
Antibiotic treatment was performed most often in phase
I with a rate of 97.5% (phase I vs. phases 0, II, III; P ≤
0.01; c
2 test). The primarily used antibiotics during this
time were carbapenems and glycopeptides.
Additional analyses, referring to the various phases
and results of blood cultures were performed, including
the SOFA score, PCT levels and the requirement of
mechanical ventilation and renal replacement therapy
on the day the corresponding blood culture was
sampled. No significant differences were found in the
Table 2 Characteristics of phase-dependent outcome and microbiological diagnosis
phases in relation to diagnosis phase 0 phase I phase II phase III
days prior to diagnosis or during sepsis Day -10 to Day -1 Day 1 to Day 5 Day 6 to Day 15 Day 16 to Day 150
# of patients alive at onset of phase, # 999 999 886 791
# of non survivors during phase, # 113 95 100
relative # of non survivors wrt all non survivors, # (%) 36.7 (113/308) 30.8 (95/308) 32.5 (100/308)
relative numbers of non survivors during phase, # (%) 11.3 (113/999) 10.7 (95/886) 12.6 (100/791)
# of drawn bc during phase, # 250 882 461 524
relative # of bc per patient alive, # (%) 25.0 (250/999)§ 88.3 (882/999)§ 52 (461/886)§ 66.2 (524/791)§
# of all positive bc during phase, # 49 173 96 146
relative # of positive bc during phase, # (%) 19.6 (49/250) 19.6 (173/882)* 20.8 (96/461) 27.9 (146/524)*
# of positive bc without CNS during phase, # 24 131 52 80
relative # of positive bc without CNS during phase, # (%) 9.6 (24/250) 14.9 (131/882)* 11.3 (52/461) 15.3 (80/524)*
Outcome of patients enrolled (n = 999) with severe sepsis or septic shock is shown corresponding to the distinct phases as defined in Figure 1, starting with
phase 0 including a period of 10 days prior to diagnosis of sepsis up to the end of phase III at Day 150. Also, the absolute numbers of drawn blood culture
samples, the rate of blood culture samples per number of patients, the rate of all positive blood cultures (including CNS) and the rate of positive blood cultures
without CNS are presented. CNS, Coagulase negative staphylococci; §, indicates statistically significant difference between all phases (P ≤ 0.05; c
2 test); *,
indicates statistically significant difference compared to phase 0 and II (P ≤ 0.05; c
2 test); #, absolute numbers; %, relative number; bc, blood cultures; wrt, with
respect to.
Table 3 Epidemiology of isolated microorganisms
microorganisms phase 0 phase I phase II phase III
number of positive bc without CNS, # 26 143 56 90
typically opportunistic bacteria (TOB), % (#) 7.7 (2) 9.1 (13) 14.3 (8) 17.8 (16)*
Candida spp. overall, % (#) 7.7 (2) 12.6 (18) 35.7 (19)§ 30 (27)§
pathogenic bacteria, % (#) 88.5 (23) 78.3 (112) 51.8 (29) 52.2 (47)
CNS ssp. overall, # 28 52 53 78
Isolated microorganisms from blood cultures of patients with severe sepsis or septic shock are demonstrated. The absolute as well as relative numbers are given
in dependency of defined phases. Others include all other isolated pathogen and presented separately in the online supplement (Additional file 1: Table S1). CNS
are also presented but excluded from relative analyses. CNS, Coagulase negative staphylococci; bc, blood cultures; *, indicates statistically significant difference
compared to phase I (P ≤ 0.05; c
2 test); §, indicates statistically significant difference compared to phase 0 and phase I (P ≤ 0.05; c
2 test).
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mechanical ventilations were found in patients with
positive blood cultures during observation phase I,
phase II and phase III (bc
- vs. bc
+ in phases I, II, III; P ≤
0.05; c
2 test and ANOVA). For the use of renal replace-
ment therapy this was true for phase I and III (bc
- vs.
bc
+ in phases I, III; P ≤ 0.05; c
2 test).
Discussion
Our findings demonstrate in a large retrospective clini-
cal study, the presence of three distinct mortailty peaks
and two nadirs in the course of the monitored mortality
rates. We were, therefore, able to identify three clinical
phases, phase I - approximately until Day 5 after the
onset of sepsis, phase II - the following days until Day
15, and phase III - beginning at Day 16, strictly deter-
mined by such peaks and nadirs. A total of 63.3% of all
deaths occurred during the defined late phases II and
III, which implicates a broad clinical significance.
Furthermore, our data demonstrate a significantly
renewed rate of positive blood cultures occurring in
phase III of sepsis, as well as the highest rates of TOB
in this phase. High positive rates of blood cultures, and
especially the rise of TOB during this phase, may indi-
cate either an inability to overcome underlying infec-
tions or a possible increase in secondary infections. The
Table 4 Patients characteristics and the use of antimicrobials
phases in relation to diagnosis phase 0 phase I phase II phase III
Overall
# of patients on ICU during phase, # 661 999 690 327
SOFA Score, mean ± SD 8.5 ± 3.6 9.6 ± 3.8* 8.4 ± 4.0 7.1 ± 3.9
PCT, mean ± SD 5.0 ± 10.8 10.3 ± 23.5* 3.2 ± 8.5 2.0 ± 4.9
Requirement of mechanical ventilation, %
(#)
78.8 (521) 90.9 (908)* 82.8 (571) 83.8 (274)
Requirement of renal replacement
therapy, % (#)
13.2 (87)§ 27.7 (277) 28.7 (198) 30.9 (101)
Treatment with antimycotica, % (#) 5.1 (34)
2 10.6 (106)
2 17.5 (121)
2 28.7 (94)
2
Amphotericin 2.6 (17) 3 (30) 4.8 (33) 8 (26)
Fluconazole/Itroconazole/Ketoconazole 2 (13) 5.3 (53) 9.6 (66) 20.8 (68)
Voriconazole 1.1 (7) 1.8 (18) 4.1 (28) 5.2 (17)
Echinocadine (Anidulafungin/Caspofungin) 0.3 (2) 1.3 (13) 1.9 (13) 3.4 (11)
Treatment with antibiotica, % (#) 75.2 (497)
2 97.5 (974)
2 91.6 (632)
2 81.3 (266)
2
Glycopeptides (Teichoplanin/Vancomycine) 10.3 (68) 19.2 (192) 31.3 (216) 34.3 (112)
aminoglycosides 5.3 (35) 7.9 (79) 7.5 (52) 10.7 (35)
Glycylcyclines 1.2 (8) 1.8 (18) 4.6 (32) 11.3 (37)
quinolones 11.8 (78) 18.1 (181) 24.8 (171) 38.2 (125)
carbapenems 15.8 (104) 35.2 (352) 48.1 (332) 40.1 (131)
cephalosporins (3rd/4th generation) 11.8 (78) 14.4 (144) 14.3 (99) 20.2 (66)
tetracyclines 0 (0) 0.2 (2) 0.1 (1) 0.3 (1)
ansamycins 2 (13) 2.7 (27) 2.8 (19) 3.4 (11)
oxazolidinones 1.4 (9) 2.4 (24) 3.5 (24) 8 (26)
penicillin 39.2 (259) 57.1 (570) 39.9 (275) 27.5 (90)
others+ 31.3 (207) 29.5 (295) 28.4 (196) 27.2 (89)
In dependency of bloodculture results bc - bc + bc - bc + bc - bc + bc - bc +
SOFA Score, mean ± SD 9.19 ± 3.93 9.29 ±
4.02
10.02 ± 3.58 10.52 ± 3.67 9.58 ± 3.7 10.18 ±
4.53
8.7 ± 3.51 8.42 ±
4.07
PCT, mean ± SD 5.24 ± 7.38 8.1 ±
11.34
12.12 ±
25.25
20.86 ±
43.82³
3.09 ±
7.82
6.68 ±
12.32³
2.07 ± 4.12 4.89 ±
12.5³
Requirement of mechanical ventilation, %
(#)
76.4 (120/
157)
100 (7/7) 79.3 (521/
657)
95.4 (103/
108)³
66 (210/
318)
92.5 (37/
40)³
44.8 (126/
281)
79.2 (38/
48)³
Requirement of renal replacement
therapy, % (#)
85.7 (36/42) 100 (2/2) 84.9 (141/
166)
100 (30/30)³ 81.8 (54/
66)
90.9 (10/
11)
48.2 (39/81) 85.7 (18/
21)³
Selected characteristics and antimicrobial treatment of patients corresponding to the distinct phases are demonstrated. The absolute, relative numbers and mean
± SDs are given. CNS, coagulase negative staphylococci; +, others include cephalosporins of the first and second generation, lincosamides, folic acid antagonists,
macrolide antibiotics and nitroimidazole; #, absolute numbers; %, relative number; bc, blood cultures; *, indicates statistically significant difference compared to
phase 0, phase II and phase III (P ≤ 0.05; ANOVA and c
2 test); §, indicates statistically significant difference compared to phase I, phase II and phase III (P ≤ 0.01;
ANOVA);
2, indicates statistically significant differences between all phases (P ≤ 0.05; ANOVA); ³, indicates statistically significant difference compared to bc
- (P ≤
0.05; ANOVA and c
2 test).
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all to data from available literature and representative of
practice patterns [14,15]. However, we observed an
expected and significant reduction in the numbers of
drawn specimens per patient in phase II and, surpris-
ingly, a significant increase in phase III.
The rates of positive cultures ranged from 9.6% prior
to diagnosis, significantly up to 14.9% during phase I,
dropping during phase II to levels of 11.3% and rising
again to 15.3% during the last observational period -
phase III. These significant patterns of positive findings
and the increase of TOB from 9.1% in phase I up to
17.8% in phase III might indicate an inability to clear
persistent infections or the appearance of new, second-
ary infections, and potentially suggest the clinical signifi-
cance of the late phase of sepsis. It might be speculated
that one of the underlying reasons could be the pro-
posed immune compromised status of patients with sep-
sis developing during the progression of disease.
Additionally, the rate of Candida spp. significantly
increased from 12.6% in phase I up to 35.7% in phase II,
and to 30.0% in phase III. An underlying mechanism
might be the frequent use of antibiotics in phase I.
In this retrospective review, we attempt to explore the
clinically impacted and microbiological pattern of the
late phase of sepsis as a cause of late morbidity and
mortality by dividing sepsis, according to the observed
mortality peaks, into three periods. We detected a sig-
nificant increase of positive blood cultures drawn in
patients with sepsis at a later time point with higher
rates of TOB, which may indicate an anergic immune
system. It needs to be understood that such implications
have a number of important drawbacks due to the
design of this study. First, the demonstrated higher fre-
quency rate of positive cultures will be very sensitive to
existing practice patterns. In our ICU the decision to
draw cultures will be taken according to the guidelines
recommending a sampling by signs and symptoms of
infections as a new onset of fever, chills, hypothermia,
leukocytosis, PCT (demonstrated by the high levels in
bc
+/- patients at the sampling day) or a raise in CRP,
neutropenia or left shift in differential blood count. In
our opinion, sampling based on guidelines without a
prospective investigative protocol reflects the situation
on ICU more reliably. The sampling rate clearly shows a
drop from 88.3% in phase I to 52% in phase II and a
rise up to 66.2% in phase III. This might demonstrate
the still ongoing inflammatory response in these
patients, especially after phase I and II in which almost
all of our patients had already received guideline-appro-
priate antibiotic treatment. In contrast to the early
phase, in which well described guidelines for the sam-
pling indication and procedure exist, the indication for
blood culture sampling during the late time points are
often also determined by the clinical phenotype and
may not be as precisely captured when compared to the
onset phase. This fact represents a confounder which is
very difficult to control. Within this study, we used a
definition of TOB. However, a precise definition of TOB
does not exist, and it must be pointed out that our clas-
sification was based on data from the literature and the
expert opinion of microbiologists and intensive care
physicians, which may also represent a drawback with
respect to derived implications. A further limitation of
this study might be that there is important informative
censoring going on; patients who die early contribute to
the initial blood culture sampling quota but obviously
not to the later ones. In contrast, patients who did well
and left the ICU and were sampled later were still
included in our analyses. Patients who did well and left
the hospital were not observed further. However, all
three scenarios provoke no bias for the rate of positive
blood cultures. Also limiting might be the fact that the
number and the duration of uses of a central venous
catheter were not included in our analyses. Only the
requirement of mechanical ventilation and renal replace-
ment therapy as additional risk factors for infections
were analyzed in greater detail. This study shows that
patients with sepsis treated on our ICU at a later time
point (>16 days) were still or even more likely to exhibit
a positive blood culture in comparison to earlier time
points and that such patients are more prone to develop
TOBs. Of course, these results are not necessarily a
legitimate or validated proxy for an anergic immune sys-
tem, but due to the absence of a clinically established
and relevant indicator for immune suppression in daily
practices, the data might serve as further hints for this
hypothesis, which has been much more clearly described
in models of experimental sepsis.
Conclusions
Most of the adjunctive clinical trials that were con-
ducted with the aim to treat sepsis focused on early and
anti-inflammatory mechanisms abrogating hyper-inflam-
mation, with most of them failing to deliver the antici-
pated results [16-22]. Only a few trials were designed
with a strategy aimed at the later phases or at improving
immune suppression [23-25]. However, both strategies
have so far not resulted in new therapeutics capable of
significantly improving outcomes of septic patients. Our
data demonstrate that the later phase of sepsis is asso-
ciated with a significant re-increase of positive blood
culture results, especially opportunistic bacteria and
fungi, and that a majority of all deaths occurred after
D a y5 .T h e s ed a t ah a v eal a r g ep o t e n t i a li m p a c to n
treatment, monitoring and outcome of septic patients.
However, the underlying mechanisms are so far not well
understood. It, therefore, appears to be warranted to pay
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Page 6 of 8more attention to the late phase of sepsis and to develop
strategies detecting the patients’ host immune response
level.
Key messages
￿ The time course of disease in a large population of
patients suffering from severe sepsis or septic shock
was characterized by three different mortality peaks,
which suggests that these patients undergo phases
which may also be dominated by different underly-
ing pathophysiological mechanisms.
￿ The late phase of sepsis is characterized by a sig-
nificant resurgence of positive blood culture findings,
which underlines the importance of the innate
immune responses in this phase.
￿ Positive microbiological findings of opportunistic
bacteria and Candida spp. increase over the length
of ICU stay in patients with severe sepsis and septic
shock.
￿ In sepsis, diagnostic tools monitoring the immune
status as well as therapies aimed at restoring the
immune response are urgently needed.
Additional material
Additional file 1: Additional Table S1. Supplement Table
1Epidemiology of isolated microorganisms. Isolated microorganisms
from blood cultures of patients with severe sepsis or septic shock are
listed. The absolute as well as relative numbers are given dependent on
the pre-defined phases. CNS are also presented but excluded from
relative analyses.
Abbreviations
#: numbers; *: indicates statistically significant differences P ≤0.05; %: relative
number; χ
2: Chi-square test; abs: absolute numbers; bc: blood cultures; bc
+/-:
positive or negative blood cultures; CNS: coagulase negative staphylococci;
PCT: procalcitonin; SOFA score: Sequential Organ Failure Assessment score;
TOB: typically opportunistic bacteria; wrt: with respect to.
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